Cyanidel borchure

The cranberry extract CyaniDel is produced by using a Biosfered Srl proprietary technology. It is first titrated with the BL-DMAC method to obtain the total amount of PACs and subsequently is analyzed by liquid chromatography coupled to mass spectrometry (HPLC-ESI-MS/MS) for the assessment of the content of the PAC A (and the possible presence of PAC B), and for the quantification of cyanidin and delphinidin.

A convenient and reliable source of PACs for UTI treatment

Extractive techniques

Extractive techniques

The extraction technique at low temperatures (20-30 °C) developed by Biosfered Srl yields an enriched fraction of bioactive cyanidin and delphinidin, along with 5% PACs. The product is partially soluble in water.

This offers several advantages:
The chemical characterization is based on the quantitative BL-DMAC method for PAC-A and the qualitative/quantitative liquid chromatography coupled to mass spectrometry analysis for the accurate identification and quantification of PACs, cyanidin and delphinidin;
The analytical methods used ensure a high quality of CyaniDel® bioactive compounds;
The precise quantification allows the exact and reliable formulation of products based on CyaniDel®;
CyaniDel® represents a convenient and reliable source of PACs for UTI treatment;
CyaniDel® contains a high content of cyanidin and delphinidin glycosides along with 5% PACs (based on BL-DMAC method).

UTI AND DOSAGE OF PACS

UTI AND DOSAGE OF PACS

In humans, administration of a cranberry dried extract standardized in PACs (DMAC) at doses containing 72 mg of PAC per day, divided in two doses of 36 mg in the morning and evening, offers protection against bacterial adhesion and virulence in the urinary tract (Howell et al. BMC Infect. Dis. 2010, 10:94).
CyaniDel contains 5% PACs (based on BL-DMAC method) and represents a convenient and reliable source of PACs for UTI treatment.